Biora Therapeutics (BIOR) Competitors

Biora Therapeutics (NASDAQ:BIOR) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.

Is BIOR or SPRB more profitable?

Biora Therapeutics has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Biora Therapeutics' return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biora Therapeutics	N/A	N/A	-332.47%
Spruce Biosciences	-555.23%	-62.10%	-47.49%

Does the MarketBeat Community prefer BIOR or SPRB?

Spruce Biosciences received 31 more outperform votes than Biora Therapeutics when rated by MarketBeat users. However, 80.00% of users gave Biora Therapeutics an outperform vote while only 54.17% of users gave Spruce Biosciences an outperform vote.

Company	Underperform	Outperform
Biora Therapeutics	Outperform Votes 8 80.00%	Underperform Votes 2 20.00%
Spruce Biosciences	Outperform Votes 39 54.17%	Underperform Votes 33 45.83%

Which has preferable valuation and earnings, BIOR or SPRB?

Spruce Biosciences has higher revenue and earnings than Biora Therapeutics. Spruce Biosciences is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biora Therapeutics	$892K	0.69	-$124.11M	-$13.04	-0.01
Spruce Biosciences	$4.91M	0.67	-$47.92M	-$1.32	-0.06

Which has more volatility and risk, BIOR or SPRB?

Biora Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500.

Does the media prefer BIOR or SPRB?

In the previous week, Spruce Biosciences had 3 more articles in the media than Biora Therapeutics. MarketBeat recorded 3 mentions for Spruce Biosciences and 0 mentions for Biora Therapeutics. Spruce Biosciences' average media sentiment score of 0.36 beat Biora Therapeutics' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Biora Therapeutics	Neutral
Spruce Biosciences	Neutral

Do insiders & institutionals believe in BIOR or SPRB?

43.7% of Biora Therapeutics shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 51.1% of Biora Therapeutics shares are held by insiders. Comparatively, 6.9% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Do analysts rate BIOR or SPRB?

Biora Therapeutics presently has a consensus target price of $23.00, suggesting a potential upside of 16,811.76%. Spruce Biosciences has a consensus target price of $1.75, suggesting a potential upside of 2,158.06%. Given Biora Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Biora Therapeutics is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biora Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Spruce Biosciences	0 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Biora Therapeutics and Spruce Biosciences tied by winning 9 of the 18 factors compared between the two stocks.